Navigation Links
Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- Vitro Studies for Promising Alzheimer's Drug

LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce positive results were attained with its late-stage preclinical/nonclinical testing of Caprospinol (SP-233), with well recognized in-vitro models.

Although nonclinical research results are imperfect predictors of clinical responses, laboratory animals remain the best experimental models for identifying and measuring a compound's biological activity and for predicting a drug's clinical effects. Because animal studies are performed before and during clinical studies, the term "nonclinical" is generally preferred to preclinical when discussing the full spectrum of in-vitro and non-human in-vivo tests associated with drug development. By studying a drug's dose-response characteristics, adverse and residual effects, Samaritan and the FDA gain valuable insights, as to a drug's probable action, and effect in humans.

Samaritan completed a series of in-vitro studies to determine SP-233's metabolic stability in liver microsomes. SP-233's results were positive since it was reported to be stable in all four species tested: human, dog, rat and mouse species. The metabolic stability of a drug candidate, e.g., drug substance in liver microsomes of different species, is determined in order to assess the potential of SP-233 to form undesired potentially toxicity or pharmacologically inactive metabolites.

In addition, positive results were reported where SP-233 was shown to have no CYP inhibition potential for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suggesting that SP-233, is unlikely to cause, or alter the metabolism of co-administered drugs, and thus cause, a drug-drug interaction, which could give rise to severe side effects.

Dr. Janet Greeson, CEO of Sam aritan Pharmaceuticals stated, "We are extremely excited about the potential of SP-233 to not only restore memory impaired by beta-amyloid toxicity but also prevent future beta-amyloid memory impairment. We anticipate these results will strengthen SP-233's investigational new drug application (IND) filed with the FDA."

Samaritan Pharmaceuticals:

"Transforming Today's Science Into Tomorrow's Cures..."

Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease, Cancer, Cardiovascular disease, HIV, and Hepatitis-C. Samaritan, in collaboration with Pharmaplaz, Ireland, is advancing SP-01A, an "oral" HIV viral-entry inhibitor, to Phase III since it has completed Phase IIb clinical studies with positive results. Samaritan has three drug candidates in nonclinical studies to develop IND applications, it's building upon the IND application for Caprospinol, SP-233, to treat Alzheimer's disease patients; evaluating the use of SP-1000 for acute coronary disease patients; and the use of SP-10T1 as an "oral treatment" for Hepatitis-C patients. In addition, Samaritan has acquired the marketing and sales rights to sell nine revenue-generating products in Greece and/or various Eastern European countries.

Website: Please register so we can notify you of upcoming conference calls, news and events.

The Samaritan Pharmaceuticals Inc. logo is available at


The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking sta tements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

-0- CONTACT: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001


Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... --  Craneware, Inc ., the healthcare market leader ... company will showcase a new version of its ... at the American Society for Health-System Pharmacists (ASHP) ... features are focused on simplifying and streamlining the ... pharmacy charges to ensure compliance and optimal revenue ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- ... of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays ... film for accurate interpretation by the radiologist. The marking utensils are so small, ... Calif., has found a way to alleviate this problem. , He developed the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):